MYL12A

Summary

MYL12A (myosin light chain 12A, HGNC:16701) is a protein-coding gene on chromosome 18p11.31, encoding Myosin regulatory light chain 12A (P19105). Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation.

This gene encodes a nonsarcomeric myosin regulatory light chain. This protein is activated by phosphorylation and regulates smooth muscle and non-muscle cell contraction. This protein may also be involved in DNA damage repair by sequestering the transcriptional regulator apoptosis-antagonizing transcription factor (AATF)/Che-1 which functions as a repressor of p53-driven apoptosis. Alternate splicing results in multiple transcript variants. A pseudogene of this gene is found on chromosome 8.

Source: NCBI Gene 10627 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 23 total — 1 pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_006471

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16701
Approved symbol	MYL12A
Name	myosin light chain 12A
Location	18p11.31
Locus type	gene with protein product
Status	Approved
Aliases	MLCB, MYL2B, MRLC3, MRCL3
Ensembl gene	ENSG00000101608
Ensembl biotype	protein_coding
Entrez	10627

Gene structure

Transcript identifiers

Ensembl transcripts: 40 — 35 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000217652, ENST00000536605, ENST00000577510, ENST00000578038, ENST00000578562, ENST00000578611, ENST00000579226, ENST00000580353, ENST00000580887, ENST00000583449, ENST00000585090, ENST00000608786, ENST00000855660, ENST00000855661, ENST00000855662, ENST00000855663, ENST00000855664, ENST00000855665, ENST00000855666, ENST00000855667, ENST00000855668, ENST00000855669, ENST00000855670, ENST00000922826, ENST00000922827, ENST00000922828, ENST00000922829, ENST00000922830, ENST00000922831, ENST00000922832, ENST00000922833, ENST00000964506, ENST00000964507, ENST00000964508, ENST00000964509, ENST00000964510, ENST00000964511, ENST00000964512, ENST00000964513, ENST00000964514

RefSeq mRNA: 4 — MANE Select: NM_006471 NM_001303047, NM_001303048, NM_001303049, NM_006471

CCDS: CCDS11830, CCDS77145

Canonical transcript exons

ENST00000217652 — 4 exons

Exon	Start	End
ENSE00001162437	3255746	3256236
ENSE00002721572	3247801	3247909
ENSE00003571508	3253233	3253428
ENSE00003785328	3253889	3254050

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 99.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 501.5171 / max 11678.2123, expressed in 1828 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
169139	482.8562	1828
169146	9.4203	198
169138	4.9669	1653
169143	1.5669	204
169137	0.9891	429
169145	0.6600	130
169149	0.4626	230
169144	0.2361	97
169140	0.1020	28
169151	0.0970	19

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.81	gold quality
right atrium auricular region	UBERON:0006631	99.73	gold quality
monocyte	CL:0000576	99.66	gold quality
leukocyte	CL:0000738	99.66	gold quality
granulocyte	CL:0000094	99.64	gold quality
right lung	UBERON:0002167	99.64	gold quality
upper lobe of left lung	UBERON:0008952	99.58	gold quality
right coronary artery	UBERON:0001625	99.57	gold quality
ascending aorta	UBERON:0001496	99.54	gold quality
thoracic aorta	UBERON:0001515	99.54	gold quality
endometrium epithelium	UBERON:0004811	99.53	gold quality
metanephros cortex	UBERON:0010533	99.53	gold quality
left coronary artery	UBERON:0001626	99.52	gold quality
rectum	UBERON:0001052	99.51	gold quality
gastrocnemius	UBERON:0001388	99.51	gold quality
gall bladder	UBERON:0002110	99.51	gold quality
popliteal artery	UBERON:0002250	99.48	gold quality
tibial artery	UBERON:0007610	99.48	gold quality
vermiform appendix	UBERON:0001154	99.44	gold quality
descending thoracic aorta	UBERON:0002345	99.43	gold quality
smooth muscle tissue	UBERON:0001135	99.42	gold quality
mucosa of transverse colon	UBERON:0004991	99.42	gold quality
muscle of leg	UBERON:0001383	99.40	gold quality
left lobe of thyroid gland	UBERON:0001120	99.36	gold quality
left uterine tube	UBERON:0001303	99.35	gold quality
tibial nerve	UBERON:0001323	99.33	gold quality
lower esophagus mucosa	UBERON:0035834	99.32	gold quality
right lobe of thyroid gland	UBERON:0001119	99.31	gold quality
small intestine Peyer’s patch	UBERON:0003454	99.30	gold quality

Single-cell (SCXA)

Detected in 33 experiment(s), a significant marker in 25.

Experiment	Marker?	Max mean expression
E-MTAB-8498	yes	6189.22
E-MTAB-10662	yes	2811.11
E-GEOD-111727	yes	2315.88
E-HCAD-1	yes	125.58
E-HCAD-4	yes	96.29
E-CURD-122	yes	54.33
E-HCAD-6	yes	48.12
E-HCAD-11	yes	46.23
E-MTAB-6701	yes	42.80
E-CURD-46	yes	41.45
E-HCAD-10	yes	37.81
E-HCAD-31	yes	26.76
E-HCAD-9	yes	25.42
E-GEOD-81547	yes	24.81
E-MTAB-8410	yes	24.47

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting MYL12A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-889-5P	99.41	68.75	1025
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-29A-5P	99.08	68.59	1813
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-140-3P	99.04	67.69	1324
HSA-MIR-622	98.99	66.48	1050
HSA-MIR-3145-3P	98.85	69.07	2031

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	myl12.2	ENSDARG00000025326
mus_musculus	Myl12a	ENSMUSG00000024048
rattus_norvegicus	Myl12a	ENSRNOG00000015278
caenorhabditis_elegans		WBGENE00003369
caenorhabditis_elegans		WBGENE00003370

Paralogs (7): MYL9 (ENSG00000101335), MYL10 (ENSG00000106436), MYL7 (ENSG00000106631), MYL2 (ENSG00000111245), MYL12B (ENSG00000118680), MYL11 (ENSG00000180209), MYL5 (ENSG00000215375)

Protein

Protein identifiers

Myosin regulatory light chain 12A — P19105 (reviewed: P19105)

Alternative names: Epididymis secretory protein Li 24, MLC-2B, Myosin RLC, Myosin regulatory light chain 2, nonsarcomeric, Myosin regulatory light chain MRLC3

All UniProt accessions (4): P19105, J3KT92, J3KTJ1, J3QRS3

UniProt curated annotations — full annotation on UniProt →

Function. Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation. Implicated in cytokinesis, receptor capping, and cell locomotion.

Subunit / interactions. Myosin is a hexamer of 2 heavy chains and 4 light chains.

Post-translational modifications. Phosphorylation increases the actin-activated myosin ATPase activity and thereby regulates the contractile activity. It is required to generate the driving force in the migration of the cells but not necessary for localization of myosin-2 at the leading edge.

Miscellaneous. This chain binds calcium.

RefSeq proteins (4): NP_001289976, NP_001289977, NP_001289978, NP_006462* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR015070	EF_hand_DJBP	Domain
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR050403	Myosin_RLC	Family

Pfam: PF08976, PF13499

UniProt features (10 total): binding site 4, domain 3, modified residue 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P19105-F1	83.59	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 41; 43; 45; 52

Post-translational modifications (2): 18, 19

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-3928664	Ephrin signaling
R-HSA-445355	Smooth Muscle Contraction
R-HSA-1266738	Developmental Biology
R-HSA-2682334	EPH-Ephrin signaling
R-HSA-397014	Muscle contraction
R-HSA-422475	Axon guidance
R-HSA-9675108	Nervous system development

MSigDB gene sets: 201 (showing top): BERENJENO_ROCK_SIGNALING_NOT_VIA_RHOA_DN, MODULE_255, BASSO_B_LYMPHOCYTE_NETWORK, XU_GH1_AUTOCRINE_TARGETS_UP, GOBP_PLATELET_ACTIVATION, MODULE_317, KEGG_TIGHT_JUNCTION, HEIDENBLAD_AMPLICON_8Q24_DN, GOBP_WOUND_HEALING, GOBP_CELL_CELL_ADHESION, NELSON_RESPONSE_TO_ANDROGEN_UP, SCHLOSSER_SERUM_RESPONSE_DN, REACTOME_SMOOTH_MUSCLE_CONTRACTION, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, GOBP_HOMOTYPIC_CELL_CELL_ADHESION

GO Biological Process (1): platelet aggregation (GO:0070527)

GO Molecular Function (4): calcium ion binding (GO:0005509), myosin heavy chain binding (GO:0032036), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): cytoplasm (GO:0005737), cytosol (GO:0005829), myosin II complex (GO:0016460), extracellular exosome (GO:0070062), myosin complex (GO:0016459)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
EPH-Ephrin signaling	1
Muscle contraction	1
Axon guidance	1
Nervous system development	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
platelet activation	1
homotypic cell-cell adhesion	1
metal ion binding	1
myosin binding	1
binding	1
cation binding	1
intracellular anatomical structure	1
cytoplasm	1
myosin complex	1
extracellular vesicle	1
actin cytoskeleton	1
protein-containing complex	1

Protein interactions and networks

STRING

2220 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYL12A	MYLK2	Q9H1R3	910
MYL12A	MYBPC3	Q14896	714
MYL12A	MYBPC2	Q14324	662
MYL12A	MYLK	Q15746	596
MYL12A	TNNI1	P19237	566
MYL12A	MYL6	P16475	541
MYL12A	MYL3	P08590	537
MYL12A	MYL6B	P14649	521
MYL12A	MYH10	P35580	519
MYL12A	ACTC1	P04270	505
MYL12A	MYH9	P35579	495
MYL12A	ITGB1	P05556	469
MYL12A	CLUL1	Q15846	419
MYL12A	RASD2	Q96D21	414
MYL12A	MYLK3	Q32MK0	412

IntAct

123 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
YWHAZ	LMNA	psi-mi:“MI:0914”(association)	0.560
LIN9	MYBL1	psi-mi:“MI:0914”(association)	0.530
ESR2		psi-mi:“MI:0914”(association)	0.500
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
FOS	MYO1C	psi-mi:“MI:2364”(proximity)	0.480
	AP3D1	psi-mi:“MI:0914”(association)	0.460
	MYL12B	psi-mi:“MI:0914”(association)	0.460
CDC42BPA	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
Cdc42bpa	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
Rock2	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
CIT	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
Cdc42bpb	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
MYLK	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
PAK1	MYL12A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
ACTB	DDX3X	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (241): MYL12A (Affinity Capture-MS), MYL12A (Two-hybrid), MYL12A (Reconstituted Complex), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS), MYL12A (Affinity Capture-MS)

ESM2 similar proteins: A0A125YHX7, A0A125YZN2, A4IF97, J9W034, O14950, O23184, O74435, O82659, P02612, P08733, P13832, P15845, P18666, P19105, P24032, P24844, P29269, P40423, P41208, P41209, P41210, P41691, P48593, P53441, Q09510, Q0IQB6, Q0IUU4, Q12798, Q24956, Q27177, Q27178, Q27179, Q2TBN3, Q32LE3, Q338P8, Q39584, Q3SEK0, Q3SEK2, Q3THE2, Q40642

Diamond homologs: A2WN93, A2WNH1, A2Y609, A3E3H0, A3E4D8, A3E4F9, A4IF97, A4UHC0, A8CEP3, A8I1Q0, B7SNI3, F1SSF9, O14950, O93409, O94739, P02597, P02598, P02608, P02609, P02610, P02611, P02612, P02613, P04112, P04113, P04353, P04464, P04466, P05419, P05944, P05963, P07461, P08051, P08052, P08733, P0DH95, P0DH96, P10916, P11120, P13543

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
DAPK1	“up-regulates activity”	MYL12A	phosphorylation
ROCK1	“up-regulates activity”	MYL12A	phosphorylation
PAK2	“up-regulates activity”	MYL12A	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 115 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
FCERI mediated MAPK activation	5	20.4×	3e-03
Smooth Muscle Contraction	5	15.6×	3e-03
Regulation of actin dynamics for phagocytic cup formation	5	10.8×	1e-02

GO biological processes:

GO term	Partners	Fold	FDR
amyloid fibril formation	5	31.7×	2e-04
canonical NF-kappaB signal transduction	5	19.3×	1e-03
Ras protein signal transduction	7	15.1×	2e-04
actin cytoskeleton organization	9	7.5×	8e-04
positive regulation of canonical NF-kappaB signal transduction	9	6.9×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

23 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	12
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1703622	GRCh37/hg19 18p11.32-11.22(chr18:136226-10172941)	Pathogenic

SpliceAI

539 predictions. Top by Δscore:

Variant	Effect	Δscore
18:3253227:A:AG	acceptor_gain	1.0000
18:3253228:A:G	acceptor_gain	1.0000
18:3253228:ATTAG:A	acceptor_gain	1.0000
18:3253229:TTA:T	acceptor_loss	1.0000
18:3253230:TAG:T	acceptor_loss	1.0000
18:3253231:A:AG	acceptor_gain	1.0000
18:3253231:AG:A	acceptor_gain	1.0000
18:3253232:G:A	acceptor_gain	1.0000
18:3253232:G:C	acceptor_loss	1.0000
18:3253232:G:GA	acceptor_gain	1.0000
18:3253232:GGA:G	acceptor_gain	1.0000
18:3253232:GGAC:G	acceptor_gain	1.0000
18:3253232:GGACT:G	acceptor_gain	1.0000
18:3253398:G:GT	donor_gain	1.0000
18:3253398:G:T	donor_gain	1.0000
18:3253399:A:T	donor_gain	1.0000
18:3253402:A:G	donor_gain	1.0000
18:3253411:A:G	donor_gain	1.0000
18:3253427:GG:G	donor_gain	1.0000
18:3253428:GG:G	donor_gain	1.0000
18:3253428:GGTAA:G	donor_loss	1.0000
18:3253429:G:GG	donor_gain	1.0000
18:3253429:GTA:G	donor_loss	1.0000
18:3253430:T:G	donor_loss	1.0000
18:3253879:A:AG	acceptor_gain	1.0000
18:3253880:A:AG	acceptor_gain	1.0000
18:3253881:A:G	acceptor_gain	1.0000
18:3253882:A:AG	acceptor_gain	1.0000
18:3253883:A:AG	acceptor_gain	1.0000
18:3253884:T:G	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000044815 (18:3248054 C>T), RS1000096580 (18:3248301 G>A), RS1000577876 (18:3250888 G>C), RS1000630252 (18:3251099 G>A), RS1000691116 (18:3250616 A>G), RS1000918107 (18:3245989 T>A,C), RS1001394576 (18:3253907 A>G), RS1001582910 (18:3249750 A>G), RS1001630486 (18:3249898 AAAAT>A), RS1001763333 (18:3255886 C>T), RS1002001990 (18:3252298 A>G), RS1002065364 (18:3251125 A>C,G), RS1002215781 (18:3256289 C>T), RS1002351392 (18:3252131 A>G), RS1002387233 (18:3247165 T>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:609628, MIM:146390

GenCC curated gene-disease

Mondo (2): Majeed syndrome (MONDO:0012316), chromosome 18p deletion syndrome (MONDO:0007800)

Orphanet (3): Majeed syndrome (Orphanet:77297), Monosomy 18p syndrome (Orphanet:1598), Partial deletion of the short arm of chromosome 18 syndrome (Orphanet:261974)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST003542_27	Night sleep phenotypes	9.000000e-06
GCST003598_51	QRS duration	3.000000e-07
GCST003598_52	QRS duration	5.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007827	nighttime rest measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
C538309	Chromosome 18p deletion syndrome (supp.)
C537839	Majeed syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724627 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.35	IC50	4480	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178785: Inhibition of MRCL3 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	4.4800	uM

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	3
sodium arsenite	increases abundance, increases expression, decreases expression, affects cotreatment	3
Valproic Acid	increases expression	3
Benzo(a)pyrene	decreases methylation, increases expression	2
GSK-J4	decreases expression	1
bisphenol F	increases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	increases expression	1
sodium arsenate	decreases expression	1
arsenite	affects binding, increases reaction	1
methylparaben	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chloropicrin	increases expression	1
K 7174	increases expression	1
torcetrapib	increases expression	1
bisphenol B	increases expression	1
bisphenol AF	increases expression	1
Bortezomib	increases expression	1
Leflunomide	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Cadmium	increases expression	1
Cisplatin	increases expression	1
Curcumin	increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Bucladesine	affects cotreatment, decreases expression	1
Diuron	decreases expression	1
Doxorubicin	affects expression	1
Estradiol	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	decreases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697515	Binding	Inhibition of MRCL3 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.